Subjective patient-reported versus objective adherence to subcutaneous interferon β-1a in multiple sclerosis using RebiSmart®: the CORE study

Background Patient adherence to treatment is key to preventing the worsening of neurological disability in multiple sclerosis (MS). The RebiSmart® autoinjector facilitates self-administration of subcutaneous interferon β-1a (sc IFN β-1a) and records objective adherence data. The CORE study was under...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC neurology Jg. 17; H. 1; S. 171 - 5
Hauptverfasser:	Zecca, Chiara, Disanto, Giulio, Mühl, Sarah, Gobbi, Claudio
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London BioMed Central 04.09.2017 BMC
Schlagworte:	Adherence Adjuvants, Immunologic - administration & dosage Adult Autoinjector Demyelinating diseases Disabled Persons Female Humans Injections, Subcutaneous Interferon beta-1a - administration & dosage Male Medication Adherence - statistics & numerical data Medicine Medicine & Public Health Middle Aged Multiple sclerosis Multiple Sclerosis - drug therapy Multiple Sclerosis, Relapsing-Remitting - drug therapy Neurochemistry Neurologists Neurology Neurosurgery Patient Compliance RebiSmart Research Article sc IFN β-1a Self Administration Self Medication - instrumentation Self Report Subcutaneous interferon β-1a Surveys and Questionnaires Adherence Multiple sclerosis Self-reported adherence Subjective adherence RebiSmart Objective adherence sc IFN β-1a Patient adherence Subcutaneous interferon β-1a Autoinjector
ISSN:	1471-2377, 1471-2377
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!